Luis Valdes Castillo
Family · Dallas, TXNPI 1942835509
Payments from drug & device makers
Across 512 payments — averaging $22.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$3K
- Gilead$2K
- Merck$1K
- Johnson & Johnson$819
- Janssen Products, LP$421
- EMD Serono, Inc.$377
- plus $3K from 26 others
What the payments were for
- Speaking & faculty fees$220%
- Food & beverage$11,01298%
- Education$2522%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 142 | $3,256 |
| Gilead | 89 | $2,362 |
| Merck | 50 | $1,169 |
| Johnson & Johnson(2 entities) | 47 | $819 |
| Janssen Products, LP | 4 | $421 |
| EMD Serono, Inc. | 25 | $377 |
| Theratechnologies Inc. | 16 | $351 |
| Novo Nordisk | 17 | $303 |
| Napo Pharmaceuticals Inc | 13 | $302 |
| AbbVie | 14 | $276 |
| Amarin Pharma, Inc. | 18 | $250 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $201 |
| AstraZeneca | 11 | $163 |
| Antares Pharma, Inc. | 9 | $145 |
| Otsuka America Pharmaceutical, Inc. | 7 | $137 |
| Lilly USA, LLC | 7 | $119 |
| GSK | 5 | $78 |
| Axsome Therapeutics, Inc. | 3 | $73 |
| Pfizer | 3 | $70 |
| Eisai Inc. | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Esperion Therapeutics, Inc. | 3 | $55 |
| Genentech USA, Inc. | 3 | $45 |
| Verity Pharmaceuticals Inc. | 2 | $34 |
| Amgen | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Boehringer Ingelheim | 1 | $22 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| Tolmar, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Halozyme Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,286 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DovatoDolutegravir Sodium/Lamivudine | 104 | $326,516 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 62 | $280,470 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 27 | $137,261 |
| DescovyEmtricitabine/Tenofov Alafenam | 44 | $120,581 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 24 | $88,680 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 21 | $80,570 |
| TivicayDolutegravir Sodium | 25 | $63,354 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 14 | $56,026 |
| PrezcobixDarunavir/Cobicistat | 20 | $52,350 |
| OzempicSemaglutide | 36 | $32,579 |
| IsentressRaltegravir Potassium | 12 | $19,100 |
| TrulicityDulaglutide | 12 | $11,791 |
| JardianceEmpagliflozin | 11 | $11,358 |
| EliquisApixaban | 12 | $5,867 |
| ValacyclovirValacyclovir Hcl | 21 | $1,830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Triumeq, Tivicay | $3,256 | $478,551153 claims |
| GileadBiktarvy, Descovy, Genvoya | $2,362 | $457,077120 claims |
| Janssen Products, LPSymtuza | $421 | $137,26127 claims |
| Johnson & JohnsonPrezcobix | $819 | $52,35020 claims |
| Novo NordiskOzempic | $303 | $32,57936 claims |
| MerckIsentress | $1,169 | $19,10012 claims |
| Lilly USA, LLCTrulicity | $119 | $11,79112 claims |
| Boehringer IngelheimJardiance | $22 | $11,35811 claims |
| PfizerEliquis | $70 | $5,86712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Dallas
- David WeirDallas$959K
- Sie ThomasDallas$197K
- Hayley McKessonDallas$165K
- Marcia HarrisDallas$156K
- Miles HortonDallas$72K
- Richard OrnbergDallas$56K
- Ifeoma OkekeDallas$48K
- Natasha SimmonsDallas$38K
- Lashonda CraneHouston$3.4M
- Luba YammineHouston$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.